Holen Sie sich die Stockscreener-App
0.836
5.69%
0.045
Vorhandelsmarkt:
.84
0.004
+0.48%
Schlusskurs vom Vortag:
$0.791
Offen:
$0.8
24-Stunden-Volumen:
2.27M
Relative Volume:
2.21
Marktkapitalisierung:
$64.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-20.31M
KGV:
-3.1607
EPS:
-0.2645
Netto-Cashflow:
$-21.07M
1W Leistung:
+3.21%
1M Leistung:
+0.60%
6M Leistung:
-18.83%
1J Leistung:
-30.91%
1-Tages-Spanne:
$0.79
$0.8534
1-Wochen-Bereich:
$0.73
$0.8597
52-Wochen-Spanne:
$0.7101
$1.53
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Firmenname
Oncolytics Biotech Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie ONCY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.836 | 64.43M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-10-06 | Eingeleitet | Maxim Group | Buy |
| 2021-02-17 | Eingeleitet | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Aktie (ONCY) Neueste Nachrichten
German PEI approves enrolment in cohort 5 of Oncolytics’ pancreatic cancer trial - MSN
Oncolytic Virus Cancer Therapy Pipeline 2024: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | CG Oncology, Targovax, Transgene, Istari Oncology, Targovax, Oncolytics Biotech - The Globe and Mail
Oncolytic Virus Cancer Therapy Pipeline 2024: Therapies, MOA - openPR
Oncolytics Biotech (TSE:ONC) Shares Down 3.4%What's Next? - MarketBeat
Oncolytics Biotech Inc. Announces Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data - Marketscreener.com
Oncolytics Bio (ONC-T) QuotePress Release - The Globe and Mail
Stocks In Play: Oncolytics Biotech Inc - Barchart
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year - Lelezard
Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data - Barchart
Oncolytics Biotech (TSE:ONC) Stock Price Down 3.4%Here's What Happened - MarketBeat
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year - Benzinga
Investors Eye Biotech Stocks as Cancer Therapies Take Center Stage in 2025 - Baystreet.ca
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech Advances Pancreatic Cancer Treatment with Regulatory Approval - TipRanks
Oncolytics Biotech (TSE:ONC) Share Price Crosses Below 200 Day Moving AverageHere's What Happened - MarketBeat
Oncolytics Biotech (TSE:ONC) Shares Pass Below 200-Day Moving Average – Here’s Why - Defense World
A Data-Based Look At Oncolytics Biotech, Inc (ONCY) - Stocks Register
Oncolytics Biotech® to Host Conference Call to Discuss First Qua - GuruFocus.com
Oncolytics Biotech (NASDAQ:ONCY) Stock Price Up 3.2% – Still a Buy? - Defense World
Oncolytics Biotech (TSE:ONC) Shares Cross Above 200-Day Moving AverageHere's What Happened - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Trading Up 3.2%What's Next? - MarketBeat
Will Oncolytics Biotech (TSE:ONC) Spend Its Cash Wisely? - Yahoo Finance
Oncolytics Biotech (TSE:ONC) Stock Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
Oncolytics Biotech (TSE:ONC) Stock Passes Above 200 Day Moving Average – Here’s Why - Defense World
Oncology In Focus: How Emerging Therapies Are Reshaping Cancer Treatment - Barchart
The Immunotherapy Boom: What It Means For The Future Of Cancer Treatment - MENAFN.COM
The Immunotherapy Boom: What It Means for the Future of Cancer Treatment - Baystreet.ca
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook - GlobeNewswire
Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data - Barchart
How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options - Informazione.it
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses - Lelezard
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector - Baystreet.ca
Oncolytics Biotech (TSE:ONC) Trading Up 14.5%Should You Buy? - MarketBeat
From Crisis To Opportunity: How Advances In Immunotherapy Are Shaping The Oncology Sector - MENAFN.COM
Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium - The Malaysian Reserve
Stocks In Play: Oncolytics Biotech Inc. - Barchart
Early-Onset Cancer Trends Spark Interest In Promising Oncology Pipelines - MENAFN.COM
Oncolytics Biotech Inc. - Baystreet.ca
Early-Onset Cancer Trends Spark Interest in Promising Oncology Pipelines - Baystreet.ca
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers - GlobeNewswire
Oncolytics Biotech's SWOT analysis: pelareorep progress boosts stock outlook - Investing.com
Oncolytics Biotech (TSE:ONC) Sets New 12-Month LowWhat's Next? - MarketBeat
Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September - The Eastern Progress Online
Finanzdaten der Oncolytics Biotech Inc-Aktie (ONCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):